Sortase-Linked Cytotoxic Constructs for Targeted Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current targeted therapeutics face challenges such as capillary leak syndrome, immunogenicity, and inadvertent toxicity due to the lack of highly specific and active toxin molecules and cell-targeting constructs, particularly for long-term or chronic applications in cancer treatment.
Innovation Solution
The development of cytotoxic serine protease polypeptides, such as granzyme B, conjugated to cell-targeting moieties via a sortase reaction, creating targeted cytotoxic constructs with a sortase linker, which can be used to treat cell proliferative diseases like cancer by selectively targeting specific cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If highly toxic molecules are used for killing target cells, then therapeutic activity is improved, but toxicity to non-targeted cells increases
Solution Approach 1:
The construct is divided into distinct functional modules: a cell-targeting moiety (antibody or ligand) that specifically binds to target cells, a linker region that connects the targeting moiety to the cytotoxic agent, and the cytotoxic agent itself (serine protease). This segmentation allows the cytotoxic agent to be delivered specifically to target cells while minimizing exposure to non-targeted cells, thereby maintaining high therapeutic activity with reduced off-target toxicity
Solution Approach 2:
The patent uses an intermediary cell-targeting moiety (such as an antibody or ligand) that mediates the delivery of the cytotoxic serine protease to specific target cells. This intermediary ensures that the highly toxic molecule only reaches its intended destination by binding to cell surface markers on target cells, preventing indiscriminate toxicity to healthy cells while maintaining potent anti-cancer activity
2Ease of manufacture
If conventional conjugation methods are used, then construction is simplified, but specificity and activity of the cytotoxic construct are reduced
Solution Approach 1:
The patent employs site-specific conjugation methods that change the parameters of the linkage between the cytotoxic agent and the targeting moiety. By using sortase-mediated conjugation or genetically encoded linkers, the construction achieves both high specificity and activity while maintaining reasonable manufacturing complexity. The conjugation method is optimized to preserve the functional integrity of both components
Solution Approach 2:
The patent introduces local quality by implementing site-specific conjugation at defined locations within the construct. Rather than random conjugation, the cytotoxic serine protease is attached at specific sites through sortase recognition sequences or genetically encoded linkers. This localized approach ensures optimal orientation and spacing, preserving the specificity and activity of both the targeting moiety and the cytotoxic agent
3Reliability
If toxin molecules are used for targeted therapy, then cytotoxic activity is improved, but immunogenicity and capillary leak syndrome occur
Solution Approach 1:
The patent creates a composite construct that combines a cell-targeting moiety (such as an antibody or ligand) with a cytotoxic serine protease through a controlled linker region. This composite structure maintains the cytotoxic activity of the protease while the antibody or ligand component reduces immunogenicity by providing a human-compatible framework. The composite design also prevents capillary leak syndrome by ensuring specific target cell delivery, thereby maintaining high cytotoxic activity with reduced systemic side effects
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These constructs demonstrate enhanced specificity and activity, reducing toxicity to non-target cells and enabling effective treatment of cell proliferative diseases, including cancer, by utilizing a sortase-mediated linkage for precise delivery of cytotoxic agents.
Implementation Method 1
contacting the compound and cell-targeting moiety with a transpeptidase, thereby producing the targeted compound
Data Source
AI summary
The invention is directed to cell-targeted cytotoxic agents, including sortase serine protease constructs. Methods for targeted cell killing for treatment of proliferative diseases, for example, cancer, are provided. Exemplary embodiments comprise an R-spondin ligand for targeting the cytotoxic agents to effect the cell killing.